Melanoma is the most aggressive form of skin cancer and is notoriously resistant to all current modalities of cancer therapy. A large set of genetic, functional and biochemical studies suggest that melanoma cells become 'bullet proof' against a variety of chemotherapeutic drugs by exploiting their intrinsic resistance to apoptosis and by reprogramming their proliferation and survival pathways during melanoma progression. In recent years, the identification of molecules involved in the regulation and execution of apoptosis, and their alteration in melanoma, have provided new insights into the molecular basis for melanoma chemoresistance. With this knowledge in hand, the challenge is now to devise strategies potent enough to compensate or bypass these cell death defects and improve the actual poor prognosis of patients at late stages of the disease. Oncogene (2003 Oncogene ( ) 22, 3138-3151. doi:10.1038 Keywords: skin cancer; drug resistance; apoptosis; cancer therapy; chemotherapeutic targets Melanoma, an aggressive tumor resistant to all standard anticancer therapies Malignant melanoma and treatment failure are, unfortunately, two intertwined clinical problems with a profound social impact. A simple look at the statistics is alarming: the lifetime risk of melanoma continues to increase steadily, reaching one in 75 (Jemal et al., 2002) . Moreover, despite an epic number of clinical trials to test a wide variety of anticancer strategies, ranging from surgery to immuno-, radio-and chemotherapy (Serrone and Hersey, 1999; Grossman and Altieri, 2001; Helmbach et al., 2001) , the average survival rate still is of 6-to-10 months (Jemal et al., 2002) .
Melanoma prognosis would not be so dismal were all melanomas detected at very early stages, that is, before the malignant melanocytes become invasive (Jemal et al., 2002) . Complete surgical excision of the primary tumor has over a 95% success rate at stages I/II and it can even substantially extend the long-term survival of patients with lymph node infiltrations (stage III) (Balch et al., 2001) . Unfortunately, melanoma lesions can remain unnoticeable or asymptomatic for extended periods of time, and even challenge well-trained dermopathologists (Megahed et al., 2002; Zalaudek et al., 2002) . Moreover, melanoma can 'explode' at stage IV (metastasis) without a clearly identifiable primary lesion (Vijuk and Coates, 1998) . At that point, metastatic melanoma cells rarely restrict to single foci, but tend to disseminate to multiple organs (Balch et al., 2001) , including brain, lungs, liver or bone, rendering surgical interventions of limited use.
The success of systemic therapy for metastatic melanoma has been minimal. Immunological approaches have been on the horizon of clinical trials ever since spontaneous remissions of melanoma tumors were observed (reviewed in Wolchok and Livingston, 2001 ), but most of these strategies have yet to be validated in large-scale randomized studies (Atkins, 2002) . Autologous or allogeneic vaccines and very efficient antigenpresenting cells (i.e. dendritic cells) are offering new hope, and complete and durable responses are being reported in a small but significant number of patients (Wolchok and Livingston, 2001) . Nonetheless, the blood-brain barrier constrains the spectrum of putative eligible individuals for vaccination therapies (unfortunately, 30% of all metastatic melanoma patients bear metastasis in the brain). Chemotherapeutic drugs could theoretically target all metastatic sites, but current treatments do not provide a significant therapeutic benefit. The alkylating agent dacarbazine (DTIC), the only FDA-approved drug for the treatment of malignant melanoma as a single agent, allows complete remissions only on 5-10% of patients (Serrone et al., 2000) . Temozolomide, a DTIC derivative with a higher permeability, has been shown to improve the response of brain metastasis, but it does not significantly increase overall survival (see Atkins, 2002 for a review). Other chemotherapeutic agents that failed in large randomized studies include nitrosoureas (carmustine, lomustine), taxanes (taxol, docetaxel), vinca alkaloids (vincristine, vinblastine) and platinum-associated drugs (cisplatin, carboplatin) . In addition, melanoma tumors are notoriously refractory to other standard drugs as doxorubicin or etoposide (see Table 1 ). Combination cocktails of chemotherapeutic drugs with IL-2 and/or IFN-a (the socalled biochemotherapy) have also failed in large phase III randomized trials (Atkins, 2002) . However, many clinical trials are underway to evaluate new therapeutic strategies and increase the fraction of durable responses (Khayat et al., 2002) .
Intrinsic versus acquired resistance of metastatic melanoma tumors
A simple look at the wide range of antineoplastic treatments that are ineffective at killing melanoma cells (Table 1) implies that the resistance mechanisms in melanoma are complex. For decades, clinicians and basic scientists have been puzzled by the fact that melanoma cells simultaneously acquire the capability to escape immune surveillance mechanisms and evade the cytotoxic action of diverse cytotoxic insults, for example, DNA damage (e.g. by irradiation, alkylation, methylation or crosslinking), microtubule destabilization or topoisomerase inhibition. Complete treatment responses after chemotherapeutic regimens rarely benefit more than 20% of the patients, and the term 'remission' is rarely used in the melanoma vocabulary. Therefore, in this tumor type, drug resistance is likely not a primary consequence of acquired genetic alterations selected during or after therapy, but rather inherent to the malignant behavior of melanoma cells at diagnosis. Here we will summarize genetic, functional and biochemical studies that support the hypothesis that melanoma cells are 'born to survive'. Their aggressive behavior stems from intrinsic survival features of their paternal melanocytes nourished by additional alterations acquired during tumor progression. These inherent survival mechanisms may contribute to the poor treatment responses typically observed in clinical settings.
The many unknowns of melanoma progression and chemoresistance
Traditionally, chemoresistance was attributed to a failure of drug-target interactions either due to a reduction of the effective concentration of the drug, via enhanced drug efflux pumps, or to detoxification enzymes (Gottesman and Pastan, 1993; Zhang et al., 1998) or the drug's target(s). How these mechanisms contribute to drug resistance in melanoma is a matter of controversy (reviewed in Grossman and Altieri, 2001; Dacarbazine (DTIC) (**), the only agent approved by the FDA for the treatment of metastatic melanoma as a single agent, provides complete or durable responses in 5-10% of metastatic melanoma patients. Indicated with (*) are drugs used in combination regimen with DTIC or IL-2/IFN-a See (Sikic, 1997) for additional information of the mode of action of the indicated antineoplastic agents Helmbach et al., 2001) . For example, although some reports indicate an upregulation of drug pumps such as P-glycoprotein and the multidrug resistance-associated protein MPR-1 upon treatment, others fail to do so Helmbach et al., 2001) . Similar contradictory results have been reported detoxification factors such as the glutathione/glutathione S transferase, associated with the inactivation of alkylating drugs. For drugs like etoposide, it has been argued that tumor cells may avoid DNA damage by actually downregulating its target, topoisomerase II (Withoff et al., 1996; Larsen and Skladanowski, 1998) . Specifically, topoisomerase II has been found to be downregulated or mutated in melanoma cells (Campain et al., 1995; Lage et al., 2000) , although its levels may not necessarily correlate with drug sensitivity (Satherley et al., 2000) . Another possible mechanism to counteract the deleterious effects of DNA-damaging drugs could be a hyperactivation of DNA repair mechanisms, either by upregulating mismatch repair genes or by potentiating enzymes that remove DNA-alkylation damage. Again, reports in the melanoma literature come in different flavors. MSH2 and other mismatch repair genes can be found upregulated (Rass et al., 2001) or downregulated (Korabiowska et al., 2000) . Therefore, the melanoma field is in great need of standardized pharmacological studies that unequivocally determine how chemotherapeutic cells are incorporated into tumor and normal melanocytes. However, the fact that chemotherapeutic drugs do activate classical DNA damage sensors in melanoma, for example, related to the p53 pathway Kramer et al., 1999; Soengas et al., 2001) , and that restoring apoptotic defects increases drug sensitivity (see below), indicates that melanoma cells actually sense the drugs but have developed clever escape alternatives to prevent or compensate for their action.
How do chemotherapeutic agents kill sensitive cells?
There has been much debate about how sensitive tumor cells respond to drug treatment (Brown and Wouters, 1999; Johnstone et al., 2002; Kaufmann and Gores, 2000) . Three decades ago, a seminal article from Kerr et al. (1972) described an experimentally induced killing of tumor cells that involved a coordinated cell disintegration following stereotypic morphologic features, including intense membrane blebbing, chromatin condensation and nuclear fragmentation. The authors coined the term 'apoptosis' to describe this form of death. It is now clear that apoptosis is one of the main contributors, although certainly not the only one (Brown and Wouters, 1999; Leist and Jaattela, 2001) , to the cytotoxic effect of conventional chemotherapeutic drugs (Kaufmann and Gores, 2000; Johnstone et al., 2002) . Indeed, proteins that control the apoptotic process hold great promise as drug targets for multiple tumor types, including melanoma (Reed, 2001a; Sotomayor et al., 2002) . However, there remains a large hurdle that must be overcome before it will be possible to take advantage of the intrinisic cell death machinery to trick the tumor cells into committing 'suicide'. Specifically, inactivation of apoptosis is a 'hallmark of cancer', an obligate ritual in the malignant transformation of normal cells (Hanahan and Weinberg, 2000) . Thus, by inactivating apoptosis, cancer cells become double winners: they enhance their chances of survival and increase their resistance to chemotherapeutic agents (Johnstone et al., 2002) .
Complexity of programmed cell death pathways
From the very early steps of embryonic development, the shape and architecture of all organs are defined by a tightly controlled balance between proliferation, differentiation and cell death . The observation that these developmental cell deaths tend to follow a morphologically similar pattern led to the proposal that, in fact, physiological forms of cell death are genetically programmed (Lockshin and Zakeri, 2001) . Frequently, but not necessarily always, those patterns resemble the classical apoptotic features that Kerr et al. initially described, and thus apoptosis is considered as the main exponent of programmed cell death. The identification of Bcl-2 as an oncogene that prevented apoptosis served as a catalyst for one of the most prolific areas of research in molecular oncology that revealed apoptosis as a critical tumor control mechanism (Lowe and Lin, 2000; Igney and Krammer, 2002; Johnstone et al., 2002) . Thus, tumor suppressors like p53 engage apoptotic pathways to prevent the accumulation of mutated or oncogenically transformed cells (Lowe et al., 1994; Soengas et al., 1999) . In fact, these p53-dependent apoptotic programs are activated in response to DNA-damaging agents, like carcinogens or UV, X or Y irradiation, and, as mentioned before, chemotherapeutic drugs (Lowe, 1995) . Therefore, it is no wonder that a large fraction of therapeutic approaches destined to improve the action of conventional anticancer drugs are aimed to target apoptotic pathways (Reed & Tomaselli, 2000; Reed, 2001a) .
The molecular mechanisms of apoptosis have been extensively studied and are discussed in detail elsewhere (see Budihardjo et al., 1999; Strasser et al., 2000; Leist and Jaattela, 2001) . Briefly, the fate of a cell depends on a complex net of sensors and positive and negative regulators whose net balance will determine whether or not apoptosis is ultimately engaged. The primary apoptotic executors are a series of cysteineaspartyl-proteases (caspases) (Thornberry and Lazebnik, 1998) , which act in a cascade ultimately leading to the cleavage of substrates that produce the characteristic features of apoptosis. The specific organization of cell death programs is extremely stimuli and cell-type dependent, and in fact there are no unique linear and defined cell death pathways. However, for simplicity they are frequently assigned to two main categories (see Figure 1 ). The so-called 'intrinsic pathway' is primarily linked to mitochondrial functions (Green and Reed, 1998) and the 'extrinsic pathway' to events that involve membrane-linked 'death receptors' (Ashkenazi and Dixit, 1998).
Intrinsic apoptosis: Apaf-1/Casp9 mitochondrial pathway A landmark study from Wang's laboratory a few years ago established a crucial role for mitochondria during apoptosis. This group showed that cytochrome c (cyt c), an essential element in the mitochondrial respiratory chain, is released from the mitochondria and acts as a critical inducer of programmed cell death (see Wang, 2001 for a review). Once in the cytosol, cyt c binds the apoptotic activator 1 (Apaf-1) and in the presence of ATP coordinates a series of conformational changes that allow the oligomerization of Apaf-1 into a ring-like complex with a sevenfold symmetry referred to as the 'apoptosome' (Acehan et al., 2002) . The apoptosome binds and activates caspase 9, which in turn recruits and activates caspases 3 and/or -6 and -7 and engages a series of proteolytic events that will culminate in a coordinated disintegration of the cell. Thus, the 'downstream' caspases 3, 6 and 7 are considered as apoptotic executors, while caspase 9 acts as a 'regulator' (Green and Kroemer, 1998) . Interestingly, while most studies indicate that caspases act primarily downstream cyt c release, recent evidence supports the requirement of caspase activation upstream of the mitochondria (Guo et al., 2002; Lassus et al., 2002; Robertson et al., 2002) .
The regulation of the mitochondrial pathway is complex. The inducers include oncogenes, low oxygen (hypoxia), growth factor deprivation, cell-cell detachment (anoikis) and other stress signals. Interestingly, many of these stimuli are encountered during tumor development. A main sensor in this pathway is the 'guardian of the genome' p53. Once activated, p53 will induce the expression of multiple transcriptional targets, including proapoptotic members of the bcl-2 family such as BAX, Puma and Noxa. These factors contribute to changes in mitochondria physiology that favor the release of cyt c (Strasser et al., 2000) . Opposing this function are antiapoptotic factors of the Bcl-2 family (Bcl-2, Bcl-xL and Mcl1 among others) (Adams and Cory, 1998) .
Additional points of control can modulate cell death after cyt c release. For example, formation of the apoptosome and activation of the downstream caspases is controlled by a family of inhibitors of apoptosis (IAPs) (Salvesen and Duckett, 2002) , which in turn are inactivated by yet other proapoptotic factors released from the mitochondria, the Smac/Diablo and Omi/OtrA (Wang, 2001) . Furthermore, as indicated below, E2F and p53 can modulate the expression of apoptotic effectors, and heat shock proteins regulate the formation of the apoptosome (Beere and Green, 2001; Muller et al., 2001; Nahle et al., 2002) .
In summary, cells respond to many signals that include tumor-related stresses and drug-induced cell death by activating the p53 tumor suppressor and Bcl-2 proapoptotic factors. These will block negative regulators of the Bcl-2 and IAP families, release cyt c and Smac/Diablo, and finally lead to apoptosis.
Extrinsic apoptosis: death receptor pathway
The extrinsic apoptotic pathway is a primary mediator of cellular immunity, but can also be implicated in the response of cancer cells to drug therapy (Ashkenazi and Dixit, 1998; Strasser et al., 2000; Fulda et al., 2001 ). This pathway is initiated by the binding of cytokines like TNF-a, TRAIL or FasL to their cognate receptors in the plasma membrane of the target cell. This binding induces the trimerization and activation of the receptor. Once activated, the cytoplasmatic domain of the receptor (namely, the 'death domain') will bind a series of adaptor proteins that in turn recruit the inactive proforms of procaspase 8 (previously called FLICE). In this multimeric death-inducing signaling complex (DISC), the caspase 8 is activated by autoproteolysis, and subsequently it cleavages and activates the downstream effector caspases (Ashkenazi and Dixit, 1998; Budihardjo et al., 1999) . This pathway is also regulated at multiple levels as the DISC can also recruit positive and negative regulators of the caspase 8 (Tschopp et al., 1998; Wajant, 2002) . In cells with low levels of caspase 8 (namely, type II cells), the formation of the DISC is not sufficient to induce directly the activation of caspase 3. In those situations, the active caspase 8 cleaves and activates a proapoptotic Bcl-2 family member named BID, which translocates to the mitochondrial membrane and there activates the 'intrinsic apoptotic pathway' (Strasser et al., 2000) . Thus, mitochondrial and death receptor pathways are tightly interconnected.
Survival features of normal melanocytes: antiapoptotic Bcl-2 family members
Melanocytes are the natural photoprotectors of the skin. Most other primary cells respond to ionizing radiation either by dying or by stalling their cell cycle in an attempt to repair irradiation-induced DNA damage. In contrast, melanocytes and their stem cell precursors get activated to secrete melanin and protect neighboring keratinocytes and other epidermal cells from further damage (Matsumura and Ananthaswamy, 2002) . Thus, melanocytes should be programmed to survive. Interestingly, the enhanced survival features of the melanocytes not only depend on specific features of the melanocytes themselves, but also on paracrine stimulation from fibroblasts and keratinocytes. Fibroblasts pay their dues to the melanocytes via bFGF, a potent survival factor of melanocytes (Ruiter et al., 2002) . Keratinocytes promote melanocyte expression of Bcl-2 by secreting neuronal growth factor (NGF) and SCF. NGF binds to its receptors in the melanocyte membrane and, in a still undefined manner, increases the levels of Bcl-2 (Zhai et al., 1996) . SCF interacts with its receptor c-KIT on the membrane and leads to the activation of the transcription factor Mitf, which will induce proliferation and differentiation of melanocyte precursors (Kawaguchi et al., 2001) . Mitf may also contribute to melanocyte survival by the transactivation of Bcl-2 (McGill et al., 2002) . The dependence of normal melanocytes on Bcl-2 for survival is illustrated by the depigmentation and loss of melanocytes of mice deficient for Bcl-2 or Mitf (Hodgkinson et al., 1993; Yamamura et al., 1996; McGill et al., 2002) .
The implication of Bcl-2 as a melanoma gene is, however, controversial. While some reports have associated high Bcl-2 levels to poor survival of metastatic melanoma patients, others indicate a downregulation of Bcl-2 during melanoma progression, and exclude the use of Bcl-2 as a prognostic factor (reviewed in Serrone and Hersey, 1999; Grossman and Altieri, 2001; Helmbach et al., 2001 ). Thus, Bcl-2 may not be the driving force for melanoma formation, but an essential survival mechanism for normal melanocytes. Tumorigenic melanoma cells may take advantage of high endogenous Bcl-2 levels to survive under adverse environmental conditions that they may encounter during metastatic transformation (see below) and, given the connection between apoptosis and drug sensitivity, bypass the effects of chemotherapeutic drugs. Consistent with this hypothesis are the observations that suppression of Bcl-2 using antisense technologies or by mutation of its transcriptional regulator Mitf induces death of melanoma cells and potentiates the effect of cancer drugs (Jansen et al., 1998; Huang, 2000; Gautschi et al., 2001; Strasberg Rieber et al., 2001; McGill et al., 2002) . Similarly, BclxL and Mcl-1, other antiapoptotic members of the Bcl-2 family, are strongly expressed in normal melanocytes, benign nevi, primary melanoma and melanoma metastases, and may contribute to melanoma resistance to therapy (Tron et al., 1995) .
Acquired apoptotic defects during melanoma progression
The extreme resistance of melanoma to chemotherapeutic drugs, and the fact that apoptotic indices are typically low in melanoma tumors, particularly at advanced stages (Staunton and Gaffney, 1995; Glinsky et al., 1997) , prompted an intense search for cell death factors altered during melanoma progression. These studies have revealed a striking breakdown of cell death control that can be associated with three types of molecular changes: (i) activation of antiapoptotic factors, (ii) inactivation of proapoptotic effectors, and (iii) reinforcement of survival signals.
Antiapoptotic factors and melanoma: survivin, Mel-IAP and FLIPs
The search for endogenous protectors of apoptosis whose function is exploited by tumor cells to enhance their survival stems, interestingly, from pioneer studies of viruses that block apoptosis in mammalian cells to favor infection (Miller, 1997) . Those studies lead to the identification of two groups of apoptotic 'brakes': IAPs and FLIPs (FLICE inhibitory proteins) later found overexpressed in multiple tumor types (Tschopp et al., 1998; Salvesen and Duckett, 2002) .
In melanoma, two members of the IAP family (survivin and ML-IAP) and FLIP have been associated with tumor progression, as they become detectable in melanocytic nevi and further overexpressed in invasive and metastatic melanomas (reviewed in Irmler et al., 1997; Grossman and Altieri, 2001 ).
The mechanism of action of survivin is unclear. In contrast to other apoptotic inhibitors, survivin expression is cell cycle dependent. At the beginning of mitosis, survivin associates with microtubules of the mitotic spindle apparently preventing the activation of caspase 3 in response to abnormal cell division (Li et al., 1998; Reed, 2001b) . The potential impact of survivin overexpression on melanoma progression is illustrated by xenograft studies, where a dominant-negative mutant of survivin (Thr 34 -Ala) reduced the tumorigenicity of melanoma cells injected in immunosuppressed mice. In addition, inactivation of survivin in already established melanoma xenografts induced tumor regression. Similarly, suppression of survivin can increase the sensitivity of melanoma cells to chemotherapeutic agents Grossman et al., 1999; Mesri et al., 2001; Pennati et al., 2002) . All together, these results point to survivin as a new candidate for therapeutic intervention in melanoma.
ML-AIP is also upregulated in melanoma cell lines, but absent in normal melanocytes (Vucic et al., 2000) . ML-IAP's effects on the mitochondrial pathways are considered to be related to a direct inhibition of the proapoptotic factor Smac/Diablo, and the caspases 9 and 3 (Vucic et al., 2002) . The impact of the endogenous levels of ML-IAP on melanoma chemoresistance has to be proven, but overexpression of ML-IAP in breast cancer cell lines (MCF-7) or in HeLa cells protects against the drug adriamycin and other apoptotic inducers, including TNF-a, FADD or BAX (Kasof and Gomes, 2001; Vucic et al., 2002) .
The impact of FLIP in melanoma chemoresistance is controversial. Given the fact that melanomas are traditionally resistant to multiple inducers of the caspase 8 pathway (including TNF-a, FasL and TRAIL/Apo 2L) and since FLIP is upregulated in a subset of melanoma tumors, it was logical to propose that high FLIPs levels were responsible for this resistance in vivo (Irmler et al., 1997; Bullani et al., 2001) . Although overexpression of FLIP increases the resistance of melanoma cells to both TRAIL and FasL (Bullani et al., 2001) , the endogenous levels of FLIP may not necessarily correlate with drug response in patients (Ugurel et al., 1999; Zhang et al., 1999) . Nevertheless, the caspase 8 pathway can be disabled by additional complex mechanisms that include the downregulation of death receptors or the expression of decoy receptors (see Hersey and Zhang, 2001 for a recent review). All together, all these defects in the caspase 8 pathway are likely to render melanoma cells refractory to immune surveillance, but their specific contribution to drug resistance needs further investigation.
p53 pathway and melanoma chemoresistance: p14ARF and Apaf-1 Consistent with its role in drug-induced apoptosis, p53 mutations have been linked to chemoresistance in many settings. However, melanomas display a low frequency of p53 mutations despite their extreme chemoresistance. One explanation for this paradox is that p53 does not influence treatment responses in this tumor type or, indeed, loss of p53 actually increases drug sensitivity as has been observed in some experimental contexts (Bunz et al., 1999) . Alternatively, p53 function could be disabled by lesions that disrupt other components of the pathway. In fact, studies using mouse models of melanoma have shown that disruption of the upstream p53 regulator p14ARF can functionally replace p53 loss during melanomagenesis (Chin et al., 1997; You et al., 2002) . Analogous to the human situation, tumors arising in these mouse models present with a wild-type p53 (Chin et al., 1997) . Moreover, the abnormal phosphorylation of p53 by Chk2 kinase may contribute to the resistance of melanoma cells to radiotherapy (Satyamoorthy et al., 2000a) .
Disruption of apoptosis downstream of p53 may alleviate pressure to mutate p53 and simultaneously decrease drug sensitivity (Schmitt et al., 2002a, b) . For example, Apaf-1 and caspase 9 can be essential downstream effectors of p53-induced apoptosis and their disruption can facilitate oncogenic transformation of cultured fibroblasts (Soengas et al., 1999) . In melanomas, Apaf-1 protein and mRNA expression are frequently downregulated in metastatic cell lines and tumor specimens (Soengas et al., 2001) . Interestingly, Apaf-1 protein levels can be restored by addition of the methylation inhibitor 5-aza-2 0 -deoxycytidine (5aza2dC), suggesting that DNA methylation contributes to suppression of Apaf-1 levels. Whether methylation blocks Apaf-1 mRNA expression directly by interfering with the recruitment of transcription factors at the Apaf-1 promoter or by affecting a regulator of Apaf-1 expression remains an open question. In any case, Apaf-1 downregulation compromises the apoptotic response of melanoma cells in response to p53 activation (Soengas et al., 2001) or E2F-1 (Furukawa et al., 2002) . Restoring physiological levels of Apaf-1 through gene transfer or 5aza2dC treatment enhances chemosensitivity, alleviating cell death defects associated with reduced Apaf-1 expression (Soengas et al., 2001) . These results raise the possibility that restoring Apaf-1 regulation to some melanomas would have therapeutic benefit.
Survival signaling in melanoma
All cells in the organism have the potential to die, and skin is no exception (Haake et al., 1998) . Among the main forces limiting cell death to its appropriate and physiological levels are survival signals derived from the activation of the PI3K/AKT/PTEN and the NF-kB and Raf/MAPK pathways. These signaling cascades are organized in intricate networks, and a detailed description of their regulation and outcome is outside the scope of this review. Below is a summary of how these pathways may contribute to melanoma resistance, and recent attempts to switch their negative effect on cell death with therapeutic intentions.
PI3K/AKT/PTEN pathway
This pathway is typically engaged in response to multiple mitogens (including oncogenes such as Ras) that bind to receptor kinases at the plasma membrane and lead to the activation of the phosphoinositide 3-kinase (PI3K) (Cantley, 2002) . Once activated, PI3K converts the lipid PIP 2 into PIP 3 . PIP 3 activates the protein kinase B/AKT which, in turn, targets multiple factors involved in cell proliferation, migration and survival. Regarding survival functions, AKT promotes the transcription of Bcl-XL, and the inactivation of the proapoptotic protein BAD, caspase 9, and the transcription factor FKHRL1 (an inducer of a number of proapoptotic factors). In addition, AKT can activate NF-kB and potentiate its survival functions, illustrating the intricate crosstalk between both pathways (Cantley, 2002 ) (see Figure 2) . Such a prosurvival force is too dangerous to be unchecked (Baldwin, 2001) , and thus mammalian cells have developed intrinsic mechanisms to regulate AKT activity. At the center of these protective mechanisms is the tumor suppressor PTEN, a phosphatase that targets PIP 3 and prevents the activation of AKT (Maehama et al., 2001) . Therefore, PTEN counteracts survival signals and promotes apoptosis. Moreover, feedback loops have been recently found between PTEN and the p53 tumor suppressor pathway (Mayo et al., 2002) (Stambolic et al., 2001) . One-third of primary melanomas and about 50% of metastatic melanoma cell lines showed reduced expression of PTEN as a result of allelic deletion, mutation or transcriptional silencing (Birck et al., 2000; Zhou et al., 2000) , suggesting that inactivation of PTEN is a late, but frequent, event on melanomagenesis (Guldberg et al., 1997; Celebi et al., 2000; Poetsch et al., 2001; Whiteman et al., 2002) .
Multiple lines of evidence point to the PI3K/AKT/ PTEN pathway as a putative candidate for therapeutic intervention in melanoma. First, PTEN overexpression can revert the invasive phenotype of human and mouse melanoma cell lines (Hwang et al., 2001; Kotelevets et al., 2001) . Second, elevated PTEN activity may sensitize cells to chemotherapeutic drugs (Mayo et al., 2002) . Moreover, although no activating mutations have been identified in the AKT gene in melanoma (Waldmann et al., 2001 (Waldmann et al., , 2002 , blocking its function by targeting the PI3K (with wortmannin or LY294002 for example) inhibits cell proliferation and reduces the sensitivity of melanoma cells to UV radiation (Krasilnikov et al., 1999; Wellbrock et al., 1999) .
The NF-kB pathway NF-kB is a transcription factor considered 'at the crossroads of life and death' by its function as a modulator of inflammation, angiogenesis, cell cycle, differentiation, adhesion, migration and survival (Karin and Lin, 2002) . In the context of cell death control, NFkB modulates the expression of a plethora of survival factors that interfere with mitochondrial and death receptor-mediated apoptosis (Karin and Lin, 2002 ) (see Figure 2) . In melanoma cells, the NF-kB pathway can be altered by upregulation of the NF-kB subunits p50 and Rel A (Meyskens et al., 1999; McNulty et al., 2001) and downregulation of the NF-kB inhibitor IkB (Yang & Richmond, 2001; Dhawan and Richmond, 2002) . Consequently, downstream NF-kB targets like c-myc, Apoptosis and melanoma chemoresistance MS Soengas and SW Lowe cyclin D1, the antiapoptotic factor TRAF2, the invasion-associated proteins Mel-CAM or the proangiogenic chemokine GRO are also frequently upregulated in melanoma (Baldwin, 2001) . Given its pleiotropic effects on survival and oncogenesis, the NF-kB pathway is a promising target for new anticancer agents (Orlowski and Baldwin, 2002) . In melanoma, gene transfer approaches have been used to inactivate Rel A (McNulty et al., 2001) and overexpress the IkB (Bakker et al., 1999; Huang et al., 2000) , suggesting that disruption of NF-kB may be of therapeutic interest (see below and Table 2 ).
Ras and B-RAF pathways
Oncogenic mutations on Ras-family members have been shown to impinge at multiple levels on AKT/NF-kB, Raf/MAPK and Ral/Rho signaling pathways (Malumbres and Pellicer, 1998). As a result, a cocktail of powerful survival signals is orchestrated to disengage cell cycle checkpoint controls, favor metastasis and block proapoptotic stimuli. In support of this hypothesis, overexpression of N-Ras in human melanoma cells enhances Bcl-2 expression and contributes to a higher tumorigenicity and drug resistance in mouse xenotransplant models (i.e. subcutaneous injections) (Borner et al., 1999) . Chin and collaborators have generated melanomas in the context of a specific genetic background (INK4a/ARF deficiency) by conditional overexpression of H-Ras in melanocytes. Interestingly, once the tumors were formed, downregulation of H-Ras expression led to a marked tumor regression by enhanced apoptosis of the tumor cells and also on the host-derived endothelial cells (Chin et al., 1999) . These results underscore the autocrine and paracrine effect of Rasdependent signals on cell survival, and illustrate once again the close connection between cell proliferation and cell death. Recent high-throughput analyses of genetic alterations in human cancers have injected additional excitement to the contribution of the Ras pathway to melanoma development. Specifically, B-Raf, a Ras effector, was found to be mutated in 66% of human melanomas. Mutations are restricted to a few single amino-acid changes (primarily on V599) that render a constitutive active kinase with transforming properties in NIH3T3 cells (Davies et al., 2002) . Interestingly, previous studies indicate that wild-type B-Raf may Table 2 Summary of gene therapy approaches in melanoma cells (C), mouse xenograft models (M), skin reconstructs (SR) and human clinical trials (H). Indicated are published strategies to activate proapoptotic effectors, inactivate antiapoptotic factors and survival signaling pathways inhibit programmed cell death downstream of cyt c release (Erhardt et al., 1999) . Whether melanomas depend on BRAF for tumor maintenance has to be proven. If the case, small molecules that inhibit B-Raf kinase activity may be the first step towards rational therapy of human melanoma.
Nonapoptotic drug response programs

Caspase-independent cell death
Mounting evidence indicates that in addition to apoptosis, nonapoptotic mechanisms may also contribute to the outcome of cancer therapy (Johnson, 2000; Leist and Jaattela, 2001; Turk et al., 2001) . For example, inactivation of noncaspase proteases like cathepsins, granzymes, and calpains has been recently associated with the resistance of melanoma cells to inducers of the extrinsinc cell death pathway such as TRAIL (Hersey and Zhang, 2001 ). An unexpected factor that may modulate melanoma drug sensitivity is the heat-shock protein 70 (Hsp70). In addition to its role in controlling the folding of different cellular proteins involved in cell cycle and apoptosis (King et al., 2001; Peng et al., 2001) , Hsp70 antagonizes the caspase-independent apoptotic inducer factor AIF (Ravagnan et al., 2001) . On the other hand, Hsp70 may also interfere with classical mitochondrial cell death pathways by preventing the oligomerization of Apaf-1 (Saleh et al., 2000) and/or by blocking the recruitment of casp9 to the apoptosome (Beere et al., 2000) . In melanoma, Hsp70 was shown to be upregulated in a subset of primary tumors and cell lines (Dressel et al., 1998; Ricaniadis et al., 2001) . The extent to which Hsp70 contributes to melanoma chemoresistance in vivo is unknown, but melanoma cells overexpressing Hsp70 have a higher resistance to UV irradiation (Park et al., 2000) .
Resistance to caspase-independent cell death may also be mediated by inactivation of the protein melanoma differentiation-associated gene-7 (mda-7). This protein is expressed in normal and early melanoma lesions, but downregulated in advanced melanoma (Ellerhorst et al., 2002) . Mda-7 induces apoptosis preferentially in melanoma tumor cells but not in normal melanocytes (Caudell et al., 2002) , at least in part by activating the MAPK pathway and downregulating Bcl-2 (Sarkar et al., 2002) . Provocative results in tumor cells indicate that the proapoptotic function of mda-7 is independent of the p53, p16, Rb, Ras, BAX and the caspase 3 status (Mhashilkar et al., 2001) . Moreover, adenoviral expression of mda-7 in melanoma cells is effective at inducing cell death and, therefore, this gene is a candidate for gene therapy (Mhashilkar et al., 2001) .
Cellular senescence
Multiple DNA-damaging drugs induce cell cycle arrest before activating cell death programs. Interestingly, recent results from cultured tumor lines (Chang et al., 2002) , mouse models (Schmitt et al., 2002b) and human patients (te Poele et al., 2002) have revealed that antineoplastic drugs can induce a permanent cell cycle arrest that resembles replicative senescence. This druginduced senescence may serve as a secondary break to tumor development, particularly under situations where apoptosis is compromised (Schmitt et al., 2002b) . Like apoptosis, senescence is a genetically controlled cellular process and susceptible to inactivation by mutation. As a consequence, mutations in genes involved in cellular senescence may also contribute to drug resistance. One of these genes is the product of the p16INK4a gene (Serrano et al., 1997) , also associated with senescence of human melanocytes and inactivated in melanoma (Bennett and Medrano, 2002) . The above-indicated results in mouse and human settings warrant further studies of alternative, nonapoptotic resistance mechanisms in melanoma cells.
The when and why of melanoma resistance
The above discussion underscores the fact that melanoma cells inactivate many sensors, regulators and effectors of apoptotic and nonapoptotic pathways. However, inactivation of cell death is not unique to melanoma, but is a 'hallmark' of cancer (Hanahan and Weinberg, 2000) . Why then are statistics favorable for some other cancers, even at advanced phases (e.g. survival rate of almost 90% for stage IV follicular lymphoma, Aviles et al., 2002) , while melanoma is so recalcitrant?
A probably too simplistic explanation is that melanoma cells are more efficient in the manner they wire cell death and survival pathways, not only by suppressing their own critical tumor control mechanisms but also those of neighboring stromal cells. An unexpected 'byproduct' of those autocrine and paracrine tumorigenic events is extreme drug resistance.
The precise order of events in the malignant transformation of the melanocytes is still part of the 'black box' of melanomagenesis (Chin et al., 1998; Herlyn et al., 2001) . Among the immediate hurdles the melanocytes have overcome, are the consequences of their abnormal hyperproliferation. Oncogenes are long known for their dual effect on promoting S phase entry and sensitizing cells to proapoptotic signals (Evan and Littlewood, 1998) . Recently, E2F family members, key mediators of oncogenic activation and constitutively active in melanoma (Halaban et al., 2000) , have been shown to increase the levels of Apaf-1 and regulatory and effector caspases, as well as other proapoptotic inducers such as c-myc or cyclin D1 (Muller et al., 2001; Nahle et al., 2002) . As a consequence, early lesions in the Rb pathway might create selective pressure to mutate components of the apoptotic machinery later on. In fact, melanoma cells with low Apaf-1 levels have an increased resistance to E2F-1-induced cell death (Furukawa et al., 2002) .
Dissociation of melanocytes from keratinocytes via downregulation of E-cadherin and other cell surface markers during radial and vertical invasion may also impose strong proapoptotic signals (by anoikis) on melanocytes. The reprogramming of cell-cell adhesion molecules observed in transformed melanocytes (i.e. expression of N-cadherin, Mel-CAM or b 3 integrins, among many others) may reinforce survival signals through the inactivation of PTEN and constitutive activation of AKT, NF-kB and Ras/Raf/MAPK pathways and their downstream effectors. To note, these survival pathways not only promote proliferation and invasion, but also block both mitochondrial and death receptormediated apoptotic cell death pathways (see Figure 2) .
Finally, to succeed in their metastatic endeavor, melanoma cells must overcome stresses from hemodynamic forces during their travel along the lymph and blood vessels, evade the immune surveillance and, moreover, readapt to a conceivable profound change in their cellular environment at the distant metastasis. All these steps are likely to be favored by both inherent and acquired insensitivity to cell death.
Another puzzle is why melanoma cells display genetic alterations that are predicted to suppress apoptosis late in the program. It has been argued that inactivation of apoptotic factors acting downstream cyt c may delay cell death, but will confer little long-term survival advantage (Green and Evan, 2002) . According to this hypothesis, it would be more effective for a tumor cell to concentrate on premitochondrial events. Although it is undeniable that a complete and permanent release of cyt c from mitochondria will ultimately lead to cell death, in many settings that outcome of cyt c release is cell and context dependent. For example, NGF-deprived sympathetic neurons protected from apoptosis by caspase inhibitors maintain a structurally intact mitochondria and survive for several days after cyt c release (Neame et al., 1998; Deshmukh et al., 2000) and cells can recover to normality after re-exposure to NGF (Martinou et al., 1999) . Of note, Apaf-1, caspases 9-and 3-deficient cells mice exhibit a massive hyperplasia in the developing central nervous system, suggesting that these cells are particularly able to tolerate signals that trigger cyt c release. Interestingly, melanocytes are neuroectodermal-derived cells (Zhai et al., 1996) , and hence in these cells, lesions affecting late apoptotic events might be more effective at blocking cell death than in other cell types. The end result of all these events is the selection of aggressive and self-sufficient cells able to bypass many cell deathinducing stimuli and 'ignore' chemotherapeutic drugs.
A long way to go in melanoma research?
The last decade has been instrumental in identifying new strategies and drug targets in melanoma, and undoubtedly these advances will ultimately produce improvements in the treatment of the disease. However, the melanoma literature is conflicting and it remains unclear which pathways are essential for the development of this disease. Therefore, the melanoma field is still in great need of prognostic and diagnostic factors . Moreover, many studies have been conducted on single tumor cell lines or using a limited set of tissue samples and may not be representative of larger settings. We believe that a better understanding of melanoma genetics as well as the incorporation of more pathophysiological models (e.g. mouse models or human skin reconstructs) of melanoma development is essential to determine the contribution of specific genetic lesions to melanoma progression and drug resistance. These models have already shown that melanoma should be considered as a homeostatic disease of the skin that is not limited to the melanocytic population, but extensive to their surrounding stromal cells (Ruiter et al., 2002) . Therefore, attacking the tumor microenvironment may be as essential as targeting the melanoma cells. In this context, pharmacological studies of new neoplastic treatments should be performed under experimental settings that recapitulate the physiology of melanoma cells in vivo to increase the likelihood of success of clinical trials.
Understanding chemoresistance provides hope of better melanoma therapy
The above review has discussed the control of apoptosis in normal melanocytes and its disregulation in melanoma. This intense area of research has provided new insights into the molecular basis of drug resistance and, more importantly, developed a molecular framework that might be exploited to develop new therapies for melanoma. We have mentioned some strategies to restore apoptotic defects, promote apoptosis-independent cell death and interfere with survival pathways. These are just part of an emerging group of studies (see Table 2 ) that have served in fact as a proof of principle for the identification of putative new drug targets in melanoma.
It must be acknowledged that the materialization of those findings into suitable clinical treatments is not a straightforward enterprise. Gene transfer strategies have been traditionally hampered by a deficient delivery to the tumor cell (Sotomayor et al., 2002) . New specific adenoviral vectors, cell permeable peptides, lipid-based gene transfer approaches and, recently, RNA interference techniques may aid in the tailored targeting of a desired pathway (McCormick, 2001; Hannon, 2002) . For example, antisense therapies for Bcl-2 are currently tested in phase III clinical trials (Banerjee, 2001) , and other genes have shown efficacy in xenograft settings.
Small molecule inhibitors could in theory be a panacea for the systemic treatment of melanoma. In practice, the therapeutic window tends to be limited by substantial secondary toxicity. Structure-based rational design of specific inhibitors may be key in reducing undesired secondary and unspecific effects. These strategies have identified potent antagonists of Bcl-2 and BclxL (Degterev et al., 2001; Enyedy et al., 2001 ) that may serve as new inducers of cell death in melanoma cells.
Perhaps the most promising targets for new melanoma therapeutics are enzymes in the survival pathways that influence melanomagenesis. These pathways include many 'drugable' targets, including Akt, PI3kinase and the ras/Raf/Mapk pathway, some of which have shown efficacy in experimental settings (Krasilnikov et al., 1999; Wellbrock et al., 1999) . In particular, an interesting candidate in the Ras/MAPK pathway is the recently identified mutant BRAF protein, and efforts to target this enzyme are underway.
Alternatively, given the many ways in which apoptosis can be disrupted in melanoma, it may be worth focusing on other therapies with a broader range of action on multiple death and survival pathways. A novel anticancer agent to be considered is the proteasome inhibitor PS-341 (Adams, 2001) . Despite a broad effect on protein stability, PS-341 has been reported to act selectively on a series of tumor cells without affecting the viability of their normal counterparts. The molecular basis of this specificity is under evaluation, but it seems to be primarily associated through the inhibition of the NF-kB pathway (Adams, 2002) (of note, upregulated in melanoma). Several clinical trials are underway to test the effect of PS-341 in solid and hematological malignancies, including a phase III trial in multiple myeloma (Adams, 2002) . Interestingly, PS-341 induces efficient cell killing of melanoma cells independently of the Apaf-1 or caspase 8 levels, and thus it could bypass apoptotic deficiencies in these cells (MSS and SWL, unpublished) .
Finally, it should be kept in mind that tumor cells not only arise from mutations or deletions of specific genes but also from still largely unknown epigenetic mechanisms that alter gene expression by modifying the chromatin, or the so-called 'histone code' (Brown and Strathdee, 2002) . PTEN, p16INK4a and Apaf-1 are just some examples of proteins silenced by epigenetic events in melanoma. DNA methyltransferase and histone deacetylase inhibitors, already being tested for other tumor types (Brown and Strathdee, 2002) , could provide unexpected therapeutic benefit in melanoma cells, by interfering with survival signals, and promote apoptosis.
Given the complex rewiring of cell death and survival pathways during melanomagenesis, it is unlikely that the cure for melanoma relies in a single 'magic bullet'. Most likely, effective treatment(s) will include the combination of multiple therapies aimed to target different resistance mechanisms. Despite their many genetic and epigenetic alterations, melanoma cells still express proteins involved in the execution of the final stages of apoptosis. As indicated before, strategies specifically aimed to exploit this fact and kill melanoma cells by bypassing or overcoming upstream death defects have provided encouraging results in experimental models. These studies are being translated into clinical settings, and we should be optimistic in achieving a long-hoped victory of science over this aggressive disease.
